Stephanie Samuels, MD

Refugjati E, Li Z, Umano G, Galuppo B, Van Name M, Samuels S, Kang G, Barbieri E, Hwang J, Santoro N. Biomarkers of Glycolysis and the Tricarboxylic Acid Cycle in Youth with and without Obesity. Hormone Research In Paediatrics 2025, 1-6. PMID: 41411205, PMCID: PMC12749259, DOI: 10.1159/000548624.

Barbieri E, Bonet J, Fox D, Nelson R, Nelson M, Nelson L, Fernandez C, Van Name M, Samuels S, Caprio S, Sabati M, Galderisi A, Sherr J, Man C, Santoro N. Daily glucose variability is associated with intrahepatic fat content, β cell sensitivity, and biomarkers of glycolysis in youth with obesity. Obesity 2024, 33: 116-124. PMID: 39658509, PMCID: PMC11666407, DOI: 10.1002/oby.24175.

Finn E, Keller C, Gowey M, Savoye M, Samuels S, Fleisch A, Rogers V, Grey M, Damschroder L, Beck A, Sharifi M. Improving access to first‐line treatment for pediatric obesity: Lessons from the dissemination of SmartMoves. Obesity 2024, 32: 1745-1756. PMID: 39192771, PMCID: PMC11875074, DOI: 10.1002/oby.24107.

Hu P, Samuels S, Sharifi M. Overview of the Treatment of Pediatric Obesity and the 2023 Clinical Practice Guidelines. Pediatric Clinics Of North America 2024, 71: 919-926. PMID: 39343501, DOI: 10.1016/j.pcl.2024.06.005.

Samuels S, Chajecki A, Hu P, Kayser M, Weyman K, Pan B, Brown E, Van Name M, Wolf R. Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c. Diabetes Obesity And Metabolism 2024, 26: 1305-1313. PMID: 38229444, DOI: 10.1111/dom.15430.

SAMUELS S, CHAJECKI A, HU P, KAYSER M, WEYMAN K, PAN B, BROWN E, VAN NAME M, WOLF R. 1100-P: Real-World Use of GLP-1 Agonists in Youth with Type 2 Diabetes Is Associated with Improvements in Hemoglobin A1c—A Multicenter Analysis. Diabetes 2023, 72 DOI: 10.2337/db23-1100-p.

Galuppo B, Umano G, Li Z, Van Name M, Samuels S, Kien C, Cline G, Wagner D, Barbieri E, Tricò D, Santoro N. Comparison of Metabolic Response to Colonic Fermentation in Lean Youth vs Youth With Obesity. JAMA Network Open 2023, 6: e2312530. PMID: 37159195, PMCID: PMC10170343, DOI: 10.1001/jamanetworkopen.2023.12530.

Slusher A, Hu P, Samuels S, Tokoglu F, Lat J, Li Z, Alguard M, Strober J, Vatner D, Shabanova V, Caprio S. Rising NAFLD and metabolic severity during the Sars‐CoV‐2 pandemic among children with obesity in the United States. Obesity 2023, 31: 1383-1391. PMID: 36694381, PMCID: PMC10186584, DOI: 10.1002/oby.23728.

Samuels S, Hu P, Maciejewski K, Li F, Dziura J, Savoye M, Sharifi M. Real‐world effectiveness of the Bright Bodies healthy lifestyle intervention for childhood obesity. Obesity 2022, 31: 203-213. PMID: 36502287, PMCID: PMC9780185, DOI: 10.1002/oby.23627.

Tricò D, McCollum S, Samuels S, Santoro N, Galderisi A, Groop L, Caprio S, Shabanova V. Mechanistic Insights Into the Heterogeneity of Glucose Response Classes in Youths With Obesity: A Latent Class Trajectory Approach. Diabetes Care 2022, 45: 1841-1851. PMID: 35766976, PMCID: PMC9346992, DOI: 10.2337/dc22-0110.

GALDERISI A, LAT J, SAMUELS S, PIERPONT B, VAN NAME M, SANTORO N, CAPRIO S. 342-OR: Low Incretin Effect Is Associated with Longitudinal Decline of Beta-Cell Function and Insulin Sensitivity in Obese Youth. Diabetes 2022, 71 DOI: 10.2337/db22-342-or.

Savoye M, Rose P, Samuels S, Tamborlane W, Caprio S, Van Name M. The Yale Bright Bodies Lifestyle Intervention Program: An Intensive Lifestyle Intervention for Obese Children and Adolescents With and Without T2D. Contemporary Endocrinology 2021, 203-216. DOI: 10.1007/978-3-030-64133-7_19.

Samuels S, Van Name M, Guandalini C, Tamborlane W, Caprio S. Current Treatment of Pediatric Type 2 Diabetes. Contemporary Endocrinology 2021, 191-202. DOI: 10.1007/978-3-030-64133-7_18.

Trico D, Galderisi A, Galuppo B, Pierpont B, Samuels S, Santoro N, Caprio S. Fatty liver, irrespective of ethnicity, is associated with reduced insulin clearance and insulin resistance in obese youths. Endocrine Abstracts 2020 DOI: 10.1530/endoabs.70.aep256.